Chemoradiation Therapy with Docetaxel/Nedaplatin and Fluorouracil for Patients Older than 80 Years with Advanced Esophageal Cancer
1)Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School
2)Department of Surgery, Nippon Medical School Tama Nagayama Hospital
The purpose of this study was to evaluate the safety and efficacy of chemoradiation therapy with docetaxel, nedaplatin and fluorouracil (5-FU) for patients older than 80 years with advanced esophageal cancer. Three patients were enrolled and received the combination of docetaxel (30 mg/m2 on day 1), nedaplatin (10 mg/body on days 1∼5), and 5-FU (250 mg/m2 on days 1∼5) with radiation (50.4 to 60 Gy in 1.8 to 2-Gy fractions over 6 weeks). Macroscopic and pathologic examinations after treatment showed no esophageal cancers; therefore complete responses were achieved in all patients, and the overall response rate was 100%. Myelosuppressions with grade 2 leukopenia occurred in 2 patients (66%), and grade 3 leukopenia occurred in 1 patient (33%). This chemoradiation therapy is effective and well tolerated by patients older than 80 years with advanced esophageal cancer.
日医大医会誌 2012; 8(2), 143-146
esophageal carcinoma, elderly patient, chemoradiation therapy
Takeshi Matsutani, Department of Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan